Briacell Therapeutics Corp T.BCT

Alternate Symbol(s): BCTX | BCTXW

Healthcare Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

TSX:BCT - Post by User

Briacell Therapeutics Corp

<< Previous

Bullboard Posts

Next >>

Post by Pocketfulofhopeon Jan 07, 2021 8:35pm

117 Views

Post# 32250995

Up coming potential catalysts

Q2 -- Bria-OTS - authorization by FDA ( 1st patient dosed)

Q3 Bria-OTS pre-reg study data

Q4 registration study - Bria-IMT + checkpoint inhibitor

these milestones set the stage for a potentially prosperous 2022. The resent up tick in volume suggest we are on point for Q2 .. we have 31% insider ownership so any positive news should give this a nice push.. I should add they have had discussions with several Big Pharma companies. Maybe a partnership is in the pipeline. Great luck all let's hope for another green one tomorrow ..

<< Previous

Bullboard Posts

Next >>

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project